A Systemic Analysis of S-1 Regimens for Treatment of Patients with Colon Cancer

Abstract

Background: Fluorouracil-based regimens have been widely accepted and recommended in the guidelines for treating patients with early or advanced staged colon cancer, although results are controversial. Here we performed a systemic analysis to evaluate the impact of S-1 based regimens on response and survival of patients with colon cancer. Methods: Clinical studies evaluating the impact of S-1 based regimens on response and survival of patients with colon cancer were identified using a predefined search strategy. Summary response rates (RRs) to treatment were calculated. Results: Six clinical studies which including 227 patients with advanced colorectal cancer were considered eligible for inclusion. Two studies were conducted using combination of S-1 and Oxaliplatin, and four studies featured S-1 and irinotecan. Systemic analysis showed that, in all patients, pooled RRs was 43.17%. Major adverse effects were hematological toxicities, gastrointestinal disturbance, neurosensory toxicity. No treatment related death occurred. Conclusion: This systemic analysis suggests that S-1 based regimens, both with oxaliplatin or irinotean are associated with acceptable response and toxicity in patients with colon cancer.

Meta-analysis of Six Randomized Control Trials of Chemotherapy Plus Anti-HER Monoclonal Antibody for Advanced Gastric and Gastroesophageal Cancer

“…S-1 is also proved to be an effective adjuvant treatment for East Asian patients who have undergone gastrectomy and S-1 based regimens are associated with acceptable response and toxicity in patients with colon cancer (Sakuramoto et al, 2007;Zhang et al, 2014). However, a meta-analysis indicated that neoadjuvant chemotherapy is not effective in 3-year disease-free survival and the adverse effects in gastrointestinal problems and leukopenia is relative high (Li et al, 2010).…”

Clinical Observations on Associations Between the UGT1A1 Genotype and Severe Toxicity of Irinotecan

“…Irinotecan (CPT-11) is an S-phase-specific, semisynthetic derivative of camptothecin that interferes with DNA replication and cell division by inhibiting topoisomerase I (Fukuoka et al, 1992) and is now used widely, especially for colorectal and lung cancers (Negoro et al, 1991;Cunningham, et al, 1998;Kudoh et al, 1998;Rougier et al, 1998;Masuda et al, 1999;Uygun et al, 2013;Wei et al, 2013;Wu et al, 2013;Bozkurt et al, 2014;Zhang et al, 2014). Although it prolongs survival, patients who treated with chemotherapy include irinotecan is often accompanied by unpredictable and sever side effects.…”